FFA
DNLI icon

Farther Finance Advisors’s Denali Therapeutics DNLI Stock Holding History

Farther Finance Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8K Buy
537
+282
+111% +$5.79K ﹤0.01% 4221
2026
Q1 		$5.02K Buy
255
+53
+26% +$1.05K ﹤0.01% 4491
2025
Q4 		$3.33K Buy
202
+75
+59% +$1.27K ﹤0.01% 4489
2025
Q3 		$1.84K Buy
127
+20
+19% +$287 ﹤0.01% 4165
2025
Q2 		$1.5K Buy
107
+100
+1,429% +$1.41K ﹤0.01% 3793
2025
Q1 		$86 Sell
7
-28
-80% -$536 ﹤0.01% 4085
2024
Q4 		$713 Sell
35
-72
-67% -$1.84K ﹤0.01% 3355
2024
Q3 		$3.13K Buy
107
+27
+34% +$669 ﹤0.01% 2828
2024
Q2 		$1.76K Buy
80
+45
+129% +$864 ﹤0.01% 2844
2024
Q1 		$720 Sell
35
-49
-58% -$921 ﹤0.01% 2899
2023
Q4 		$1.8K Buy
+84
New +$1.66K ﹤0.01% 2475

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Farther Finance Advisors's DNLI Position: Q2 2026 in Review

Farther Finance Advisors increased its Denali Therapeutics (DNLI) stake by 111% in Q2 2026, buying an estimated $5.79K and bringing the position to 537 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4221.

Farther Finance Advisors first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Farther Finance Advisors held 537 shares of Denali Therapeutics worth $13.8K as of Q2 2026.
  • Farther Finance Advisors bought 282 Denali Therapeutics shares in Q2 2026, an estimated $5.79K.
  • Denali Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4221 holding.
  • Farther Finance Advisors first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.